Volume : 08, Issue : 07, July – 2021
Title:
10.EFFECT OF EMPAGLIFLOZIN ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH HEART FAILURE: A SYSTEMATIC REVIEW
Authors :
Muhammad Hammad Sharif, Maleeha Shah*, Madeeha Khalique, Muhammad Hassan Jan, Atif Ahmed, Muhammad Irfan
Abstract :
Empagliflozin is a newer category of anti-diabetic drug. It is a SGLT2 inhibitor and exerts its action by inhibiting the reabsorption of glucose from the tubules in the kidneys that leads to loss of glucose in the urine. There has been great interest in the use of empagliflozin in atherosclerotic cardiovascular diseases, not because of its glucose lowering properties, but due to its improved cardiovascular outcomes. The positive cardiovascular outcomes associated with the use of empagliflozin is independent of its glucose lowering aspect and involves its action on lowering of blood pressure, weight loss and decrease in visceral fat. Several randomized clinical trials have been conducted on the effect of empagliflozin on cardiovascular mortality and they have clearly shown the dominance of empagliflozin as compared to the other glucose lowering therapies. This has revolutionized the use of empagliflozin in patients outside the spectrum of diabetes mellitus and has allowed its entry in the category of drugs which improve cardiovascular mortality. We have conducted this study to further gather clinical evidence regarding the cardiovascular mortality outcomes associated with the use of empaglifozin as compared to other glucose lowering therapies and whether this outcome is also evident in patients without type 2 diabetes mellitus.
Keywords: Empagliflozin, Heart failure, Diabetes, Cardiovascular outcomes, Lowering blood pressure, Weight loss
Cite This Article:
Please cite this article in press Maleeha Shah et al., Effect Of Empagliflozin On Cardiovascular Outcomes In Patients With Heart Failure: A Systematic Review.., Indo Am. J. P. Sci, 2021; 08(07).
Number of Downloads : 10
References:
1. Zelniker, T., Wiviott, S., Raz, I., Im, K., Goodrich, E., Bonaca, M., Mosenzon, O., Kato, E., Cahn, A., Furtado, R., Bhatt, D., Leiter, L., McGuire, D., Wilding, J. and Sabatine, M., 2019. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. The Lancet, 393(10166), pp.31-39.
2. Verma, S. and McMurray, J., 2018. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia, 61(10), pp.2108-2117.
3. Griffin M, Rao V, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C et al. Empagliflozin in Heart Failure. Circulation, 2020;142(11):1028-1039.
4. Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in Acute Heart Failure Syndromes: An Essential Target of Evaluation and Treatment. The American Journal of Medicine, 2006;119(12):S3-S10.
5. Schnermann J. Juxtaglomerular cell complex in the regulation of renal salt excretion. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 1998;274(2):R263-R279.
6. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine. 2016;374(11):1092-1094.
7. Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 2015;373(22):2117-2128.
8. Kosiborod M, Cavender M, Fu A, Wilding J, Khunti K, Holl R et al. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs. Circulation, 2017;136(3):249-259.
9. Kosiborod M, Lam C, Kohsaka S, Kim D, Karasik A, Shaw J et al. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs. Journal of the American College of Cardiology, 2018;71(23):2628-2639.
10. Verma S, Mazer C, Fitchett D, Inzucchi S, Pfarr E, George J et al. Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial. Diabetologia, 2018;61(8):1712-1723.
11. Zanchi A, Burnier M, Muller M, Ghajarzadeh‐Wurzner A, Maillard M, Loncle N et al. Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo‐Controlled Trial. Journal of the American Heart Association, 2020;9(13).
12. Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine, 2015;373(22):2117-2128.
13. Tanaka A, Shimabukuro M, Machii N, Teragawa H, Okada Y, Shima K et al. Effect of Empagliflozin on Endothelial Function in Patients With Type 2 Diabetes and Cardiovascular Disease: Results from the Multicenter, Randomized, Placebo-Controlled, Double-Blind EMBLEM Trial. Diabetes Care, 2019;42(10):e159-e161.